Poseida Therapeutics nominates new CAR-T candidate under Roche collaboration

Poseida Therapeutics (PSTX) announced the nomination of a new development candidate under its collaboration with Roche (RHHBY). The nomination triggered a $15M milestone payment from Roche to Poseida. The new candidate is an allogeneic, dual CAR-T therapy targeting known antigens expressed in hematologic malignancies, including multiple myeloma. The large capacity of Poseida’s non-viral transposon-based DNA delivery system enables the insertion of genes for two full length chimeric antigen receptors into T stem cell memory cells. Poseida and Roche now have three programs under their collaboration, which was established in August 2022 to develop allogeneic CAR-T therapies directed to hematologic malignancies.